31.45
0.07 (0.22%)
| Previous Close | 31.38 |
| Open | 31.85 |
| Volume | 779,044 |
| Avg. Volume (3M) | 441,385 |
| Market Cap | 1,598,664,192 |
| Price / Sales | 3.91 |
| Price / Book | 4.13 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -6.48% |
| Operating Margin (TTM) | -3.85% |
| Diluted EPS (TTM) | -0.430 |
| Quarterly Revenue Growth (YOY) | 33.20% |
| Quarterly Earnings Growth (YOY) | 864.20% |
| Total Debt/Equity (MRQ) | 114.67% |
| Current Ratio (MRQ) | 6.36 |
| Operating Cash Flow (TTM) | 31.08 M |
| Levered Free Cash Flow (TTM) | -21.36 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -5.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunocore Holdings plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.18% |
| % Held by Institutions | 97.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (HC Wainwright & Co., 217.97%) | Buy |
| Median | 87.50 (178.22%) | |
| Low | 75.00 (Needham, 138.47%) | Buy |
| Average | 87.50 (178.22%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 31.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 75.00 (138.47%) | Buy | 32.04 |
| HC Wainwright & Co. | 04 Feb 2026 | 100.00 (217.97%) | Buy | 31.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Levicept Announces the Appointment of James Sandy as Chief Development Officer |
| 30 Jan 2026 | Announcement | Immunocore announces R&D leadership evolution |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |